experiments support a causal link between intracellular PAg accumulation, decreased BTN3A1 membrane mobility and ensuing Vγ9Vδ2 T cell activation. This study demonstrates a novel role played by B7-like molecules in human γδ T cell antigenic activation, and paves the way for new strategies to improve the efficiency of immunotherapies using Vγ9Vδ2 T cells.
Introduction
γδ T cells are key players in the immune surveillance of cellular distress, thanks to their ability to recognize conserved determinants upregulated following inflammation, infection or cell transformation.
1-2 While γδ T cell receptors (TCR) contribute to detection of danger-associated determinants, ligands for these receptors have been identified in a few cases only. 3 Thus the antigenic specificity of γδ T cells and their fine activation modalities in response to cell stress remain largely unknown.
One of the best studied γδ T cell subsets in humans expresses Vγ9Vδ2 TCR and predominates in blood, comprising several percent of the whole peripheral lymphoid pool in most adults. Vγ9Vδ2 For personal use only. on January 12, 2018. by guest www.bloodjournal.org From Some BTN receptors exert non-immunological functions, e.g. milk fat globule formation for BTN1A1. Others, in line with their homology with several B7-related coinhibitory receptors, can up-or down-modulate TCR-induced T cell activation and contribute to dampening of inflammatory responses. 17, [20] [21] This can result from either direct engagement of BTN receptors expressed on responding T cells by target cell ligands, or interactions involving target cell BTN molecules and responding T cellderived ligands. [22] [23] [24] [25] In this study, we provide evidences that ubiquitous human CD277/BTN3A plays a key role in PAg-induced activation of Vγ9Vδ2 T cells in both tumor and infectious contexts and that CD277-dependent activation is conferred by Vγ9Vδ2
TCR. Our results suggest that intracellular PAg accumulation is associated with membrane reorganization of CD277 molecules, that in turn leads to Vγ9Vδ2 T cell activation, and bring new insights into the mechanisms linking metabolic and infectious distress and human γδ T cell activation. We also describe agonist and blocking CD277-specific antibodies that could be used for the immunotherapeutic modulation of Vγ9Vδ2 T cell responses towards tumor or infected cells.
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Materials and Methods

Monoclonal antibodies and reagents
The following monoclonal antibodies were from Beckman Coulter: phycoerythrincyanin 5.1-anti-TCRγδ (#IMMU510) and anti-CD69 (#TP1.55.3), fluorescein isothiocyanate-anti-Vδ2 (#IMMU389), phycoerythrin-cyanin 7-and purified anti-CD3ε (#UCHT1) or BD Biosciences: mouse IgG1, allophycocyanin-TCRγδ (#B1), allophycocyanin-H7 (analog of cyanin 7)-anti-CD3 (#SK7), fluorescein isothiocyanate-or phycoerythrin-cyanin 5.1-CD107a (#H4A3), anti-CD107b (#H4B4). Fluorescein isothiocyanate-or phycoerythrin-anti-IFN-γ (#B27) and phycoerythrin-or allophycocyanin-anti-TNF-α (MAb11) were used for intracellular stainings. Purified anti-CD3 (#OKT3) was kindly provided by H. Vié. Alexa-647-labeled goat anti-mouse IgG and anti-IgG1 were from Invitrogen. Mouse anti-CD277 mAbs (clones #7.2, #20.1, #103.2) were generated, produced and purified as described. 26 Synthetic bromohydrin pyrophosphate (BrHPP) was kindly provided by Innate Pharma. Pamidronate was obtained from Mayne Pharma. Monensin A, phorbol-12-myristate-13-acetate (PMA), ionomycin, leucoagglutinin, mevastatin and sec-butylamine were purchased from Sigma-Aldrich. Guinea pig myelin basic protein (gpMBP) was kindly provided by R. Dörries. Live/Dead, Lipofectamine and hygromycin were from Invitrogen. Recombinant human IL-2 (rhIL-2) was from Chiron Therapeutics. Green fluorescent protein strain of Mycobacterium bovis bacillus Calmette-Guérin (GFP-BCG) was provided by F. Altare.
Cells
Peripheral blood mononuclear cells (PBMC) of human healthy donors were isolated from blood samples obtained from the Etablissement Français du Sang. Human Vγ9Vδ2 (clone GR4, polyclonal lines GUI and AL), Vγ8Vδ3 (clone 73R9), iNKT (polyclonal line MAD11), αβ CD8 pos (HCV-1/A2-restricted clone 13) T cells were cultured in complete RPMI1640 medium (10% FCS, 2 mM L-glutamine, 10 μg/ml streptomycin, 100 IU/ml penicillin, 300 IU/ml rhIL-2) as described. 35 Human polyclonal αβ T cells expressing the Vγ9Vδ2 G115 TCR after retroviral transduction were generated as described. 27 Human Jurkat T cells (J.RT3-T3.5, β-chain-deficient variant) expressing either Vγ9Vδ2 (from clone G115) or Vγ8Vδ3 (from clone 73R9) TCR were generated as described.
28 58C-CD28 pos are αβ TCR neg 58C mouse T hybridoma cells transduced for rat/mouse CD28 expression. [29] [30] 53/4-CD28 cells are 53/4 cells (a sister clone of the rat/mouse T cell hybridoma 35/2), which express a rat αβ TCR recognizing a guinea pig MBP 
Functional assays
Target cells were pretreated for the indicated time periods with either CD277-specific mAbs or NBP (Pamidronate) at the indicated concentrations. Treated target cells were extensively washed and cocultured together with effector T cells at 37°C in complete RPMI1640 medium. T cells were also activated by either soluble PAg (BrHPP), at the indicated concentrations, or PMA and ionomycin (used, respectively, at 1 μM and 0.5 μg/ml). T cells were activated at 37˚C in the presence of 10 μM monensin and fluorochrome-labeled CD107a-and CD107b-specific mAbs, used alone or in combination. After 4 h, T cells were harvested and stained with fluorochrome-labeled TCR specific mAbs and a viability marker (Live/Dead cell marker, 0.3 μM). When indicated, intracellular stainings of IFN-γ and TNF-α were performed within the same samples. Surface expression of CD69 was measured by flow cytometry after activation for either 4 h (Jurkat) or 7 h (PBMC) at 37°C in complete RPMI 1640 medium. Data were collected on FACSCantoII, LSR or FacsCalibur cytometers (BD Biosciences) and analyzed with FlowJo software (Tree Star). TNF-α concentration was assessed by a biological assay based on WEHI164 clone 13 cell viability as described.
32 ELISpot for IFN-γ was performed as described. 27 When indicated, the cytolytic activity of human γδ T cells was also measured in standard 4 h-51 Cr release assays. Stimulation of 2Aγδ TCR MOP pos 58C-CD28 or 2Aγδ TCR MOP pos 53/4-CD28 murine hybridoma cells was performed similarly as previously described.
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Expression and knockdown of BTN3 isoforms in HEK293FT cells
See Supplemental Materials and Methods section.
Microscopy
See Supplemental Materials and Methods section.
Statistical analysis
The statistical significance of differences between populations was assessed with two-tailed Student's t-, two-way ANOVA or Mann-Whitney tests. P values of less 0.05 than were considered significant. 
Results
Broad activation of human Vγ9Vδ2 T cells by anti-CD277 antibodies
While screening mouse monoclonal antibodies (mAb) raised against isoforms of the human BTN3 (CD277) subfamily, 26 we noticed that one mAb (clone #20.1) elicited dramatic expansion and proliferation of γδ T cells in IL-2-supplemented PBMC cultures ( Figure 1A ; Supplemental Figure S1A ). Accordingly, soluble #20.1 mAb induced: ex vivo production of IFN-γ and TNF-α by γδ T cells (Figure 1B) , rapid CD69 upregulation and IFN-γ production by most Vδ2 pos -γδ PBL ex vivo ( Figure 1C ;
Supplemental Figure S1B ) and degranulation and cytokine responses of Vγ9Vδ2 T cell clones specifically ( Figure 1D ; data not shown). In agreement with recent studies, 23,25 soluble #20.1 mAb had no stimulatory effect on αβ T cells. Moreover it had no effect on Vδ2 neg -γδ PBL ( Figure 1C ) or -T cell clones ( Figure 1D ). Early activation events induced in Vγ9Vδ2 T cells by #20.1 mAb were studied by videomicroscopy. While #20.1 mAb had no effect on the intracellular Ca 2+ levels of αβ T cells, it induced a progressive increase of Ca 2+ signaling in Vγ9Vδ2 T cell clones, which became significant as of 10 min post mAb addition ( Figure 1E They can also modulate T cell co-stimulatory or co-inhibitory signals through interactions with target cell-expressed CD277. 24, 34 Thus although anti-CD277 mAb readily induced Vγ9Vδ2 T cell activation in the absence of third-party cells, this could be due to either a "direct" or "cis" effect of the Ab (CD277-induced signaling in responder Vγ9Vδ2 T cells), or an "indirect" or "trans" effect (enhanced reactivity of T cell recognition ( Figure 2C ; Supplemental Figure S3B ). This effect was not due to mAb-redirected killing or mAb-dependent cell cytotoxicity, as it did not depend on CD16, CD32 or CD64 Fc-receptors expression on target or effector cells (Supplemental Figure S3C) .
Implication of the Vγ9Vδ2 TCR in anti-CD277 mAb-induced activation
The broad stimulatory effects of anti-CD277 mAbs are limited to Vγ9Vδ2 T cells which suggests involvement of the Vγ9Vδ2 TCR. #20.1 mAb-treatment induced corecruitment of target cell-derived CD277 and effector cell-derived CD3 molecules at the target/γδ T cell interface, as shown by a confocal microscopy study ( Figure 3A) .
To assess the Vγ9Vδ2 TCR dependency of this activation more directly, we studied the responses of human and mouse T cell lines transduced with human γδ TCRs.
Unlike their non-transduced or Vγ8Vδ3 pos counterparts, 28 Vγ9Vδ2 pos human Jurkat T lymphoma cells were readily activated by #20.1 mAb ( Figure 3B) . Similarly, Vγ9Vδ2 1 1 TCR gene transfer into non-transformed human CD4 pos αβ T cells 27 conferred T cell responsiveness to #20.1 mAb-and NBP-pretreated human target cells ( Figure 3C ).
We also tested the reactivity of murine T cell hybridomas transduced with a human Vγ9Vδ2 TCR derived from a PAg-reactive γδ T cell clone. Human Raji cells treated with #20.1 mAb, but not cells treated with control IgG, triggered IL-2 responses of both Vγ9Vδ2 TCR murine transductants (Figures 3D-E Mutation of these residues affected responses of Jurkat Vγ9Vδ2 TCR transfectants to both NBP-and anti-CD277-treated cells, which suggests close similarities between both activation processes (Supplemental Figure S4A ; data not shown). This observation led us to assess by mass spectrometric analysis the levels of two major shRNA most effective for CD277 knock-down (sh#284) provoked the greatest reduction in γδ T cell responses. In contrast, CD277 knock-down had no effect on antigenic activation of αβ T cells (not shown).
Taken together, these results indicate a unique mandatory role played by CD277 in tumor or infectious contexts associated with spontaneous Vγ9Vδ2 T cell activation and in Vγ9Vδ2 T cell responses elicited by PAg.
Key contribution of BTN3A1 to PAg-induced activation of Vγ9Vδ2 T cells
Since CD277-specific mAbs cross-react with all three isoforms of CD277, 26 they did not allow their role played in Vγ9Vδ2 T cell activation to be assessed. To address this, we generated cells expressing only one of each of the isoforms, by transfecting CD277-knock-down (sh#284) HEK293 cells with mutated cDNAs designed to confer resistance to knock-down without changing the protein sequence coded ( Figure 6A ). Since EmGFP, unlike mCherry, was fused directly to the carboxy-terminus end of the B30.2 domain without any spacer sequence, the weak functionality of EmGFP- (Figures 7A-B) .
Importantly, NBP treatment decreased mobility of mCherry-BTN3A1 chimeras, but had no effect on mCherry-BTN3A2 chimeras ( Figure 7C ). Furthermore treatment with mevalonate pathway inhibitors like mevastatin that act upstream of PAg production did not change the mobility of mCherry-BTN3A1 chimeras, and actually inhibited the effects of NBPs on this phenomenon. This suggests that NBP-induced changes of BTN3A1 mobility is primarily due to PAg accumulation, rather than downstream effects linked to the overall blockade of the mevalonate pathway.
Therefore Vγ9Vδ2 T cell activation tightly correlates with decreased CD277 membrane mobility provoked in a B30.2-dependent way by intracellular PAg accumulation.
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Discussion
Sensing of microbial and mammalian PAg is an elegant strategy for immune detection of infectious and metabolic distress exploited by a major γδ T cell subset shared by primates, but absent in other species. 2,4-5 Although expression of Vγ9Vδ2 TCR has been known for years to be a prerequisite for PAg-induced activation, 12, 39 how such small non-peptidic metabolites promote γδ TCR engagement has remained a mystery. Our results identifying a key role for CD277, a recently identified member of the extended B7 receptor family, yield new insights into this mechanism. The key implication of the ubiquitous CD277 molecule in γδ T cell activation is consistent with the lack of tissue restriction of NBP-and PAg-induced γδ T cell responses.
11
Moreover, the lack of functional CD277 orthologues in rodents goes hand in hand with the absence of PAg-responding γδ T cell subsets in these species 2 , and the lack of Vγ9Vδ2 T cell reactivity towards NBP-or PAg-treated murine cell lines. 
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For personal use only. on January 12, 2018. by guest www.bloodjournal.org From How Vγ9Vδ2 T cells detect PAg-induced changes of CD277 remains to be determined. These changes could be sensed by the Vγ9Vδ2 TCR directly, although we failed to demonstrate cognate interactions between recombinant Vγ9Vδ2 TCR and CD277 (E.J.A., unpublished results), or to restore Vγ9Vδ2 T cell responses towards NBP-treated murine target cells after BTN3A1 transduction (C.H., R.B., M.B., E.S., unpublished results). Alternatively CD277 might promote recruitment of other receptors recognized by the Vγ9Vδ2 TCR, such as ecto-F1-ATPase which is a known ligand for Vγ9Vδ2 TCR. [44] [45] The restricted but mandatory implication of CD277 in the activation of particular human γδ T cell subsets brings to mind the mandatory role played by Skint-1, another member of the extended B7 receptor family, in the selection of murine intraepidermal γδ T cells. [16] [17] [18] While Skint-1 deficiency prevents differentiation of T cells expressing invariant Vγ5Vδ1 TCR, it has no effect on other γδ or αβ T cell compartments. Whether Skint-1 directly interacts with Vγ5Vδ1 TCR or modulates TCR engagement by yet undefined antigens remains unclear. It is striking that the human B7-related molecules which are most homologous to SKINT1 in their extracellular regions are the mouse and human butyrophilins, including CD277.
21
Therefore the implication of BTN/Skint-related members of the extended B7 receptor family in cell selection and/or peripheral activation could represent a unifying feature shared by seemingly unrelated γδ T cell subsets from distinct species.
From an applied standpoint, trials using clinical grade Vγ9Vδ2 T cell agonists 
